In addition, USP2 stabilizes Mdm2, which antagonizes the pro-apoptotic activity of p53 and possibly contributes to therapeutic resistance in cutaneous T-cell lymphoma (CTCL) [189]. This evidence concerns the gene USP2 and primary cutaneous T-cell non-Hodgkin lymphoma.